Joanna Shields, BenevolentAI CEO

As­traZeneca taps two more tar­gets from its AI part­ner, again in CKD and IPF

As­traZeneca is dou­bling down in chron­ic kid­ney dis­ease and id­io­path­ic pul­monary fi­bro­sis by se­lect­ing one tar­get for each of those via its AI-pow­ered part­ner.

Orig­i­nal­ly teamed up in 2019, the Big Phar­ma has now se­lect­ed a to­tal of five tar­gets via its UK coun­ter­part, Benev­o­len­tAI. The tal­ly in­cludes two tar­gets in CKD and three in IPF, a lung-scar­ring and breath­ing-con­stric­tion dis­ease with two ap­proved drugs — Boehringer In­gel­heim’s Ofev and Roche’s Es­bri­et, both giv­en the nod in 2014 — and a re­cent gener­ic en­try.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.